China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE: 300294)

Market Cap	14.96B
Revenue (ttm)	1.71B
Net Income (ttm)	186.10M
Shares Out	504.25M
EPS (ttm)	0.37
PE Ratio	80.42
Forward PE	25.48
Dividend	0.32 (1.06%)
Ex-Dividend Date	Oct 25, 2024

Volume	4,294,200
Open	30.75
Previous Close	30.75
Day's Range	30.59 - 31.20
52-Week Range	22.91 - 41.98
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 19, 2025

About China Resources Boya Bio-pharmaceutical Group Co.,Ltd

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. The company offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. It provides bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection products; and metformin hydrochloride enteric-coated tablets, glimepiride tablets, calcium dobesilate products, and pioglitazone hydrochloride dispersible ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,444
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2023, China Resources Boya Bio-pharmaceutical Group Co.,Ltd's revenue was 2.65 billion, a decrease of -3.87% compared to the previous year's 2.76 billion. Earnings were 237.47 million, a decrease of -45.06%.